^
    25d
    Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity. (PubMed, Mol Cancer Ther)
    The highest non-severely toxic dose was 5×108 CAR-T cells/kg. In the clinical case report, we present a case with unresectable advanced gastric cancer achieved pathological complete response 10 months after IMC002 infusion and no signs of recurrence were indicated in subsequent clinical and radiological follow-ups. IMC002 shows effectiveness and safety in CLDN18.2-positive gastric and pancreatic cancer and its favorable profiles support further clinical development.
    Preclinical • Journal
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    IMC002
    2years
    A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN18 (Claudin 18) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    CLDN18.2 positive
    |
    IMC002
    over2years
    A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Suzhou Immunofoco Biotechnology Co., Ltd
    New P1 trial • Metastases
    |
    CLDN18 (Claudin 18) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    CLDN18.2 positive
    |
    IMC002
    3years
    Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression (clinicaltrials.gov)
    P1, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2034 --> Dec 2024
    Enrollment open • Trial completion date • CAR T-Cell Therapy • Metastases
    |
    CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
    |
    IMC002
    over3years
    Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Suzhou Immunofoco Biotechnology Co., Ltd
    New P1 trial • CAR T-Cell Therapy
    |
    CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
    |
    IMC002